Latest Conference Coverage


Amit Bar-Or, MD, FRCPC

Switch to Siponimod Safe, Tolerable With No Washout, Study Finds

April 18th 2021

Results from the ongoing clinical trial will help define clinical management guidelines for switching patients with relapsing MS on other disease-modifying therapies to siponimod.


Multiple Independent Current Control DBS Associated With Improved Outcomes in Parkinson Disease

Multiple Independent Current Control DBS Associated With Improved Outcomes in Parkinson Disease

April 18th 2021

No stimulation adverse effects were reported, and patients on the MICC stimulation alone resulted in greater than 50% improvement in UPDRS motor scores.


Marian LaMonte, MD, MSN, FAAN

Simple Interventions Improve Compliance With Patient-Specific Stroke Discharge Instructions

April 17th 2021

Researchers from Ascension Saint Agnes improved compliance in their hospital in providing patient-specific, stroke-dedicated discharge instructions.


Sana Somani, MD, MBBS

Disparities in Stroke Rehabilitation: Sana Somani, MD, MBBS

April 17th 2021

The vascular neurology fellow at the University of Maryland Medical Center discussed findings that African American women had the lowest functional performance in stroke rehabilitation.


Rimegepant Safe in Patients With Prior Triptan Failure

Rimegepant Safe in Patients With Prior Triptan Failure

April 17th 2021

Serious adverse events occurred in 3.7% and 2.4% of subjects in the subgroups of patients with 1 and 2 or more triptan failures, respectively.


Role of Social Determinants in Epilepsy Treatment Delays: Joseph Sirven, MD

Role of Social Determinants in Epilepsy Treatment Delays: Joseph Sirven, MD

April 17th 2021

The professor of neurology at Mayo Clinic discussed the reasoning for the research he presented at AAN 2021 on social determinants and their impact on epilepsy treatment times.


Clive Ballard, MD

Negative Impacts on Cognition Not Observed With Pimavanserin for Dementia-Related Psychosis

April 16th 2021

The study presented at the 2021 AAN Meeting follows the complete response letter issued by the FDA to Acadia Pharmaceuticals due to deficiencies in their sNDA.


Marian LaMonte, MD, MSN, FAAN

Improving Stroke Discharge Instructions: Marian LaMonte, MD, MSN, FAAN

April 16th 2021

The chief of neurology at Ascension Saint Agnes discussed her team’s efforts to increase compliance in providing patient-specific stroke DCI.


Plasma NfL Offers Better Prognostication for Neurodegeneration Than Total Tau

Plasma NfL Offers Better Prognostication for Neurodegeneration Than Total Tau

April 16th 2021

Data from a cohort of more than 900 individuals suggest that while total tau can add cross-sectional value in certain contexts, neurofilament light served better for prognostication of cognitive decline and imaging changes.


Utilizing Aspirin to Lower Stroke Rates in Cerebral Amyloid Antipathy: Sheheryar Jamali, MD

Utilizing Aspirin to Lower Stroke Rates in Cerebral Amyloid Antipathy: Sheheryar Jamali, MD

April 16th 2021

The neurologist from Mayo Clinic discussed his abstract at AAN 2021 comparing stroke rates in patients with cerebral amyloid antipathy given treatment with aspirin.


Investigators Identify Links Between Clinical Seizure Characteristics and Continuous EEG

Investigators Identify Links Between Clinical Seizure Characteristics and Continuous EEG

April 16th 2021

Critically ill patients who were obtunded, stuporous, or comatose had pediatric lateralized epileptiform discharges, and acute brain insults were among many clinical characteristics to benefit from longer EEG.


 Kimberley Allen-Philbey, PhD candidate

Personalized Cladribine Dosing for Multiple Sclerosis

April 15th 2021

Kimberly Allen-Philbey, a PhD candidate at the Barts MS Center in London, discussed the advantages of using a personalized dosing schedule of off-label, subcutaneous cladribine.


What to Expect from the 2021 American Academy of Neurology Annual Meeting

What to Expect from the 2021 American Academy of Neurology Annual Meeting

April 14th 2021

The 2021 AAN Annual Meeting will be held virtually from April 17-22. Follow along with coverage from NeurologyLive, including expert interviews and session recaps.


Daniel Reich, MD, PhD

Finding New Therapeutic Targets in MS: Daniel Reich, MD, PhD

April 14th 2021

The senior investigator at the National Institutes of Neurological Disorders and Stroke spoke about further research his lab is conducting into MS mechanisms.


NeuroVoices: Ralph Sacco, MD, MS, on Improving Disparities and Expanding Research in Stroke Care

NeuroVoices: Ralph Sacco, MD, MS, on Improving Disparities and Expanding Research in Stroke Care

April 14th 2021

The chair of neurology and Olemberg Family Chair of Neurological Disorders at the University of Miami Miller School of Medicine discussed solutions to improve disparities in stroke care and the need for future research on social determinants of health.


Jemima Akinsanya, DO

Treating Paramagnetic Rim Lesions in Multiple Sclerosis

April 13th 2021

Jemima Akinsanya, DO, Neuroimmunology Clinical Fellow at the National Institutes of Health, discussed new studies of anakinra and tolebrutinib in MS.


Jemima Akinsanya, DO

Understanding Mechanisms of MS Chronic Inflammation: Jemima Akinsanya, DO, and Daniel Reich, MD, PhD

April 9th 2021

The duo from the National Institutes of Health discussed how monitoring and treating paramagnetic rim lesions can improve patient care in multiple sclerosis.


Need for Research on Social Determinants of Health for Stroke Outcomes: Ralph Sacco, MD, MS, FAAN, FAHA

Need for Research on Social Determinants of Health for Stroke Outcomes: Ralph Sacco, MD, MS, FAAN, FAHA

April 9th 2021

The chair of neurology and Olemberg Family Chair of Neurological Disorders at the University of Miami Miller School of Medicine detailed the reasons behind the lack of research on social determinants of health on stroke outcomes.


Improving Racial and Ethnic Disparities in Stroke Care: Ralph Sacco, MD, MS, FAAN, FAHA

Improving Racial and Ethnic Disparities in Stroke Care: Ralph Sacco, MD, MS, FAAN, FAHA

April 7th 2021

The chair of neurology and Olemberg Family Chair of Neurological Disorders at the University of Miami Miller School of Medicine provided plans of action to reduce racial and ethnic disparities in stroke.


Kimberly Allen-Philbey, PhD candidate

Chariot MS Study of Off-Label Cladribine in Advanced MS: Kimberly Allen-Philbey

April 6th 2021

The PhD candidate at the Barts MS Center in London discussed the upcoming Chariot MS study as well as further research she would like to conduct in personalized cladribine dosing.


Ways to Lower Genetic Leukodystrophies Misdiagnosis in Clinical Settings: Alise Carlson, MD

Ways to Lower Genetic Leukodystrophies Misdiagnosis in Clinical Settings: Alise Carlson, MD

April 6th 2021

Alise Carlson, MD, a resident at Cleveland Clinic, provided insight on how raising awareness for genetic leukodystrophies may ultimately improve misdiagnosis rates.


Variety of Stroke Data Presented at ISC 2021: Ralph Sacco, MD, MS, FAAN, FAHA

Variety of Stroke Data Presented at ISC 2021: Ralph Sacco, MD, MS, FAAN, FAHA

April 2nd 2021

The chair of neurology and Olemberg Family Chair of Neurological Disorders at the University of Miami Miller School of Medicine detailed a number of presentations from ISC 2021.


Benjamin Brooks, MD

IV Edaravone Reduces Chance of Death, Tracheostomy, PAV, and Hospitalization in ALS

April 1st 2021

Researchers conducted a post-hoc analysis of Study 19 to determine hazard ratios of milestone occurrences in amyotrophic lateral sclerosis.


Barry Byrne, MD, PhD

SGT-001 Shows Improvements in Key DMD Measures, Microdystrophin Expression

March 31st 2021

Preliminary results from the IGNITE-DMD trial also showed a decreased in creatine kinase levels and improvements on NSAA and PODCI.


Expanding Research on MS Diagnosis Disclosure and Long-Term Impacts: Anne Kever, PhD

Expanding Research on MS Diagnosis Disclosure and Long-Term Impacts: Anne Kever, PhD

March 31st 2021

The postdoctoral researcher at Columbia University discussed the long-term plans to gain a better understanding of MS diagnosis disclosure and how it can impact other qualities of life.


NeuroVoices: Ralph Sacco, MD, MS, on Florida Stroke Registry, Advancing Stroke Knowledge

NeuroVoices: Ralph Sacco, MD, MS, on Florida Stroke Registry, Advancing Stroke Knowledge

March 31st 2021

The chair of neurology and Olemberg Family Chair of Neurological Disorders at the University of Miami Miller School of Medicine discussed the abundance of research from the Florida Stroke Registry presented at ISC 2021.


Spencer Hutto, MD

CNS Demyelination and Autoimmune Neurology: Spencer Hutto, MD

March 30th 2021

The fellow of autoimmune neurology at Massachusetts General Hospital also discussed concerns of associations between multiple sclerosis and COVID-19.

© 2025 MJH Life Sciences

All rights reserved.